MANTLE CELL LYMPHOMA
Clinical trials for MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to spare seniors from chemo
Disease control TerminatedThis phase 2 trial tested a combination of two drugs, venetoclax and rituximab, as a first treatment for people over 60 with mantle cell lymphoma. The goal was to see if this chemo-free approach could shrink or control the cancer. However, the study was stopped early after enroll…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Cord blood transplant trial for blood cancers halted early
Disease control TerminatedThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control TerminatedThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental lymphoma drug IPH6501 tested in early trial – but study halted
Disease control TerminatedThis early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental lymphoma drug CPO107 tested in small early trial
Disease control TerminatedThis early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited informati…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New cancer drug PRO1160 tested in advanced cancers – trial ends early
Disease control TerminatedThis study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental MCL drug trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new drug called TQB3909 in 19 people with mantle cell lymphoma that had returned or stopped responding to treatment. The goal was to find a safe dose and check for side effects. However, the study was terminated early, so we have limited informatio…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Ibrutinib heart risks under the microscope: can we predict them?
Knowledge-focused TerminatedThis study aimed to understand why some people taking the cancer drug ibrutinib develop heart issues like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to try to …
Matched conditions: MANTLE CELL LYMPHOMA
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC